ImaCor, Inc. is a New York medical-device company that built the world's first and only hemodynamic transesophageal echocardiography (hTEE) platform for the intensive care unit. Its miniaturized, disposable ClariTEE probe can stay safely in a critically ill patient for up to 72 hours, giving clinicians a continuous, direct window onto the heart - preload, contractility, and right- and left-ventricular function - so they can guide fluids and drugs in real time instead of guessing. In 2022 ImaCor and Clarius Mobile Health launched the FDA-cleared Zura Handheld Hemodynamic Ultrasound, a pocket-sized, 22-ounce TEE system that puts that window in a clinician's hand.
Scott Roth is a cardiologist who spent two decades reading echocardiograms before deciding the ICU needed a faster way to see the heart. As founder and CEO of ImaCor, he built hemodynamic ultrasound (hTEE) around the disposable, pencil-thin ClariTEE probe that stays in a patient for up to 72 hours, giving clinicians a live look at cardiac filling and function instead of waiting on lab results. In 2022 ImaCor and Clarius released the Zura Handheld, billed as the world's first handheld TEE system, putting that view in a 22-ounce device.